We recently discovered a novel compound, identified as N 3,5′-cyclo-4-(β-D-ribofuranosyl)-vic-triazolo[4,5-b] pyridinin-5-one, with anti-hepatitis C virus (HCV) activity in vitro. The structure was confirmed by chemical synthesis from 2-hydroxy-5-nitropyridine. It showed anti-HCV activity with EC50 = 19.7 μM in replicon cells. Its 3′-deoxy sugar analogue was also synthesized, but was inactive against HCV in vitro.
Bibliographical noteFunding Information:
Supported in parts by NIH grants 1R43 AI-52868 (biology) and 1 R43 AI-056720 (chemistry). We would like to acknowledge the contribution of D. L. Barnard, J. D. Morrey, and D. F. Smee at the Institute for Antiviral Research at Utah State University for their testing of RNA viruses under NIH Contract No. N01-A1-85348. Dr. Schinazi is a founder and consultant of Pharmasset, Inc. His laboratory did not receive any funding from Pharmasset, Inc.